At Boehringer, AI develops new antibody-based medicines
technologies March 22, 2024 In terms of artificial intelligence, Boehringer uses a pre-trained model from IBM, enriched with its own proprietary data. (Photo: Boehringer Ingelheim) In its search for new antibody-based treatments to fight serious diseases, the pharmaceutical laboratory Boehringer Ingelheim is counting on AI. Goal: identify new drug candidates faster. AdvertisingTo accelerate the development … Read more